Publications by authors named "Luca Mologni"

59Publications

We shall overcome (drug resistance) some day.

Oncotarget 2019 Jan 4;10(2):84-85. Epub 2019 Jan 4.

Department of Medicine and Surgery, University of Milano-Bicocca, Monza, MB, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26550DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349439PMC
January 2019

Synergistic activity of dasatinib in combination with β-catenin blockade in colorectal cancer cells.

Authors:
Luca Mologni

Eur J Cancer 2018 11 12;104:231-232. Epub 2018 Oct 12.

University of Milano-Bicocca, Monza, Italy. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049183136
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2018.08.025DOI Listing
November 2018

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.

Neoplasia 2018 05 30;20(5):467-477. Epub 2018 Mar 30.

Dept. of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Clinical Research Unit, San Gerardo Hospital, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2018.02.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915992PMC
May 2018

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.

Cancers (Basel) 2018 Feb 28;10(3). Epub 2018 Feb 28.

Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin 10124, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers10030062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876637PMC
February 2018

Novel targeted therapeutics for MEN2.

Endocr Relat Cancer 2018 02;25(2):T53-T68

School of Medicine and SurgeryUniversity of Milano-Bicocca, Monza, Italy

View Article

Download full-text PDF

Source
https://erc.bioscientifica.com/view/journals/erc/25/2/ERC-17
Publisher Site
http://dx.doi.org/10.1530/ERC-17-0297DOI Listing
February 2018

Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients.

Am J Hematol 2017 10 17;92(10):E623-E625. Epub 2017 Aug 17.

School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.24865
Publisher Site
http://dx.doi.org/10.1002/ajh.24865DOI Listing
October 2017

Discovery of RET and RET Inhibitors: From Hit to Lead.

ChemMedChem 2017 08 25;12(16):1390-1398. Epub 2017 Jul 25.

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, via Marzolo 5, 35131, Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cmdc.201700243DOI Listing
August 2017

The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition.

J Cancer 2017 1;8(1):140-145. Epub 2017 Jan 1.

School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy;; Hematology and Clinical Research Unit, San Gerardo Hospital, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.15838DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264050PMC
January 2017

RET kinase inhibitors: a review of recent patents (2012-2015).

Expert Opin Ther Pat 2017 Jan 26;27(1):91-99. Epub 2016 Sep 26.

c School of Pharmaceutical Sciences , University of Geneva , Geneva , Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543776.2017.1238073DOI Listing
January 2017

Current and future treatment of anaplastic lymphoma kinase-rearranged cancer.

Authors:
Luca Mologni

World J Clin Oncol 2015 Oct;6(5):104-8

Luca Mologni, Molecular Oncology Lab, Department Health Sciences, University of Milano-Bicocca, 20900 Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5306/wjco.v6.i5.104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600184PMC
October 2015

Expanding the portfolio of anti-ALK weapons.

Authors:
Luca Mologni

Transl Lung Cancer Res 2015 Feb;4(1):5-7

Department of Health Sciences, University of Milano-Bicocca, Via Cadore 48, 20900 Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2014.07.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367714PMC
February 2015

Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.

J Natl Cancer Inst 2014 Feb;106(2):djt378

Affiliations of authors: Department of Health Sciences, University Milano Bicocca, Monza, Italy (CGP, FF, AS, SR, MC, LMo, CM, LA, RP); Hematology Unit (CGP) and Nuclear Medicine and PET Unit (CM, LG), San Gerardo Hospital, Monza, Italy; M Tettamanti Research Center, Pediatric Clinic University of Milano Bicocca, Monza, Italy (GG); Medical Genetics Laboratory, San Gerardo Hospital, Monza, Italy (ES); Istituto di Ricerca Pediatrico Fondazione Città della Speranza, Pediatric Clinic University of Padova, Padova, Italy (LMu); H.-Hartziekenhuis Roeselare-Menen vzw, Roeselare, Belgium (DD); Trillium Health Centre, Mississauga Site, Mississauga ON, Canada (MHK); Division of Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria (MS); Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany (RO); Hematology Institute, Beilinson Hospital, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (AMC); Department of Haematology and Internal Oncology, University Hospital Regensburg, Regensburg, Germany (MG); Hematology/Stem Cell Transplantation, Maisonneuve Rosemont/University of Montreal, Montreal, QC, Canada (LB); School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland (GC).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt378DOI Listing
February 2014

Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors.

Bioorg Med Chem 2014 Feb 10;22(4):1303-12. Epub 2014 Jan 10.

Université de Lyon, Laboratoire Chimie Organique 2-Glycochimie, ICBMS, UMR-5246, CNRS-Université Claude Bernard Lyon 1, Bât. 308 CPE Lyon, 43 Bd du 11 Novembre 1918, F-69622 Villeurbanne, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2014.01.007DOI Listing
February 2014

Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.

Mol Cell Endocrinol 2013 Sep 27;377(1-2):1-6. Epub 2013 Jun 27.

Dept. of Health Sciences, University of Milano-Bicocca, via Cadore 48, 20900 Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mce.2013.06.025DOI Listing
September 2013

Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.

Mol Cancer Res 2013 Feb 13;11(2):122-32. Epub 2012 Dec 13.

Department of Health Sciences, University of Milano-Bicocca, Via Cadore 48, Monza 20900, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-12-0569DOI Listing
February 2013

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.

Am J Hematol 2012 Nov 9;87(11):E125-8. Epub 2012 Oct 9.

Department of Clinical Medicine and Prevention, University of Milano-Bicocca, S. Gerardo Hospital, Monza, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23338DOI Listing
November 2012

Inhibitors of the anaplastic lymphoma kinase.

Authors:
Luca Mologni

Expert Opin Investig Drugs 2012 Jul 22;21(7):985-94. Epub 2012 May 22.

University of Milano-Bicocca, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2012.690031DOI Listing
July 2012

Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.

ChemMedChem 2011 Sep 30;6(9):1680-92. Epub 2011 Jun 30.

Division of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Helsinki, P.O. Box 56 Viikinkaari 5 E, 00014 Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cmdc.201100168DOI Listing
September 2011

Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2.

Cancer Res 2010 Sep 7;70(18):7253-63. Epub 2010 Sep 7.

University of Milano Bicocca, Monza, Italy; McGill University, Montreal, Canada; and National Cancer Institute, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-1108DOI Listing
September 2010

Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold.

Eur J Med Chem 2010 Jul 19;45(7):2919-27. Epub 2010 Mar 19.

Technische Universität Braunschweig, Institut für Pharmazeutische Chemie, Beethovenstrasse 55, D-38106 Braunschweig, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2010.03.017DOI Listing
July 2010

Valproic acid enhances bosutinib cytotoxicity in colon cancer cells.

Int J Cancer 2009 Apr;124(8):1990-6

Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.24158DOI Listing
April 2009

Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy.

Anticancer Agents Med Chem 2007 Nov;7(6):594-611

Department of Clinical Medicine, University of Milano-Bicocca, Monz, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187152007784111340DOI Listing
November 2007

Targeted deletion of the muscular dystrophy gene myotilin does not perturb muscle structure or function in mice.

Mol Cell Biol 2007 Jan 30;27(1):244-52. Epub 2006 Oct 30.

Neuroscience Program and Department of Pathology, Biomedicum Helsinki, Haartmaninkatu 8, P.O. Box 63, 00014 University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.00561-06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1800670PMC
January 2007

Inhibition of RET tyrosine kinase by SU5416.

J Mol Endocrinol 2006 Oct;37(2):199-212

Department of Clinical Medicine, Prevention and Biotechnology, University of Milan-Bicocca, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1677/jme.1.01999DOI Listing
October 2006

A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer.

Int J Biol Macromol 2006 Aug 21;39(1-3):60-5. Epub 2006 Feb 21.

Department of Experimental Oncology, National Cancer Institute, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijbiomac.2006.01.006DOI Listing
August 2006

Expression, purification, and inhibition of human RET tyrosine kinase.

Protein Expr Purif 2005 May;41(1):177-85

Department of Clinical Medicine, University of Milano-Bicocca, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pep.2005.01.002DOI Listing
May 2005

Characterization of mouse myotilin and its promoter.

Biochem Biophys Res Commun 2005 Apr;329(3):1001-9

Department of Pathology and Neuroscience Program, Biomedicum Helsinki, University of Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2005.02.074DOI Listing
April 2005